EE46 Venetoclax in Combination with Azacitidine Is Cost-Effective Vs. AZA for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.300
https://www.valueinhealthjournal.com/article/S1098-3015(22)00501-0/fulltext
Title :
EE46 Venetoclax in Combination with Azacitidine Is Cost-Effective Vs. AZA for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00501-0&doi=10.1016/j.jval.2022.04.300
First page :
Section Title :
Open access? :
No
Section Order :
10260